Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raludotatug Deruxtecan (R-DXd) in Platinum-resistant Ovarian Cancer
NCT06161025Phase 3Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2024
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial of raludotatug deruxtecan in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (5 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Objective Response Rate at 18 months and Progression-Free Survival at 26 months. Started Feb 2024; status: recruiting.
02
Drugs
raludotatug deruxtecan
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT06161025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06161025.